MedTrace Logo

Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutaneous Allergen Administration

NCT00719511 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2011-02-17

No results posted yet for this study

Summary

Evaluation of patch as specific immunotherapy in allergic patients

Conditions

Interventions

DRUG

Purified allergen dose 1 integrated in a Patch system

Epicutaneous application of a patch

DRUG

Purified allergen dose 2 integrated in a Patch system

Epicutaneous application of a patch

DRUG

Purified allergen dose 3 integrated in a Patch system

Epicutaneous application of a patch

DRUG

Purified allergen integrated in a Patch system

Epicutaneous application of a patch

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • 01 Studienregister MasterAdmins · UniversitaetsSpital Zuerich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2009-11-30
Completion
2009-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00719511 on ClinicalTrials.gov